Identification of the Epileptogenic Lobe in Neocortical Epilepsy with Proton MR Spectroscopic Imaging
Susanne G. Mueller(University of California, San Francisco), Michael W. Weiner(University of California, San Francisco), Kenneth D. Laxer(California Pacific Medical Center), Derek Flenniken(San Francisco VA Medical Center), Peter Vermathen(University Hospital of Bern), Jerome Barakos(Sutter Health), Nathan Cashdollar(San Francisco VA Medical Center), Gerald B. Matson(San Francisco VA Medical Center)
Cited by 21
Related Papers
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
|Neurology|2009|741
11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
|The Lancet Neurology|2010|696
Altered bile acid profile associates with cognitive impairment in Alzheimer's disease—An emerging role for gut microbiome
|Alzheimer s & Dementia|2018|690